Keywords: Bristol-Myers Squibb, Ambrx, Type 2 diabetes, Heart failure

Bristol-Myers teams up with Ambrx for novel biologics programs in diabetes and heart failure

Article | 23 September 2011

Print This

US drug major Bristol-Myers Squibb (NYSE: BMY) revealed yesterday that it has teamed up with privately-held California-based Ambrx for the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in